Endometriosis Market Report and Forecast 2025-2034
Description
The endometriosis market was valued at USD 691.55 Million in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 5.21% during the forecast period of 2025-2034 and attain a market value of USD 1149.20 Million by 2034.
Endometriosis Market Overview
Endometriosis is a persistent condition, characterized by the growth of tissue like the uterine lining outside the uterus, leading to pain and potential infertility, The market for endometriosis treatment is expanding due to the increasing incidence of the condition, which affects approximately 10% of the women worldwide. Key trends contributing to this growth include heightened investment in clinical trials and the development of non-hormonal treatment options. This awareness of the condition and ongoing innovation in therapeutic solutions will significantly drive the market in the forecast period.
Endometriosis Market Growth Drivers
Rising Prevalence of Endometriosis Drives Market Growth
The rising prevalence of endometriosis has significantly contributed to the growth of the market. As reported by the World Health Organization (WHO), approximately 10% (190 million) of reproductive-age women and girls are affected by this condition globally. This alarming statistic highlights the urgent need for innovative therapies and comprehensive treatment options, thereby driving market expansion and investment opportunities in the healthcare sector.
Endometriosis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Increased Funding Initiatives to Drive Market Growth
The market is witnessing transformative trends driven by increased funding initiatives from various government and non-government organizations to support endometriosis research. For instance, in March 2023, the Wellbeing of Women and the Scottish Government allocated EUR 250,000 to fund a clinical trial for a new endometriosis treatment in over 40 years. This grant facilitated the EPIC2 trial, led by researchers at the Universities of Edinburgh, Aberdeen, and Birmingham, and involving 100 women across Edinburgh and London. The trial focused on evaluating dichloroacetate as a non-hormonal, non-invasive pain management alternative, underscoring the market's shift towards innovative therapies that meet patient needs.
Increased R&D Initiatives Poised to Elevate Endometriosis Market Value
Increased research and development initiatives are expected to elevate the market value in the coming years. For instance, in September 2023, researchers at the Comprehensive Center for Pain and Addiction examined the role of the hormone prolactin in endometriosis-related pain. Their systematic review of 18 studies revealed elevated prolactin levels in affected women, pointing to its implications for pain sensitivity. Such investigations may enhance treatment approaches, addressing both endometriosis and associated pain disorders effectively.
Clinical Trial Applications to Fuel Endometriosis Market Demand
The market continues to evolve, driven by innovative clinical trial applications that aim to enhance treatment options. For instance, in May 2023, Abbott applied for the launch of modified-release dydrogesterone tablets to the Drugs Controller General of India. It is specifically designed to manage pelvic pain associated with endometriosis. This application included requests for permission to conduct a bioequivalence study and Phase-III clinical trials, which focused on comparing the efficacy of modified-release and immediate-release formulations. The trials aimed to assess quality of life improvements and reductions in endometriosis size among participants, thereby addressing critical unmet needs in the market and potentially expanding therapeutic options for patients.
Increased Focus on Inflammation Management to Drive Endometriosis Market Growth
The increasing awareness around the role of inflammation in endometriosis has significantly influenced market dynamics, driving research and development in this area. For instance, in February 2023, Chugai Pharmaceutical Co. Ltd, in collaboration with Tsukuba Primate Research Center, NIBIOHN, and Jichi Medical University Saitama Medical Center, announced research on AMY109, a promising investigational therapy aimed at managing inflammation linked to endometriosis. This focus on inflammation management highlights a growing trend, positioning the endometriosis market for expansion.
Endometriosis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Share by Route of Administration Set to Witness Significant Growth
Based on the route of administration the market is divided into oral, injectables, and others. Among these, the oral route is expected to dominate the market. Innovative oral medicines, such as Elagolix, Danazol, etc, with their potential for convenience, patient compliance, and cost-effectiveness, account for a significant share of the overall pharmaceutical landscape. This segment is poised for significant expansion during the forecast period, largely due to increasing awareness and demand for patient-friendly treatment options.
Endometriosis Market Analysis by Region
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to dominate the market due to advanced technology, strong consumer demand, and substantial investments in innovation. This region is poised for future growth with increasing adoption of digital solutions, and rising health consciousness among consumers. Additionally, the government initiatives in healthcare infrastructure enhance competitiveness, making this region a key driver of market expansion in the forecast period.
Leading Players in the Endometriosis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a global life sciences company. For endometriosis, Bayer has developed Visanne (dienogest), a progestin-only oral treatment approved for managing endometriosis symptoms by reducing pelvic pain and lesions.
Pfizer Inc.
Established in 1849, Pfizer is based in New York City, USA. The company has developed Depo-Provera (medroxyprogesterone acetate), primarily a contraceptive, but also used for treating endometriosis-related symptoms such as pelvic pain.
AbbVie Inc.
AbbVie, founded in 2013 and headquartered in North Chicago, Illinois, USA, is renowned for its biopharmaceuticals. The company developed Orilissa (elagolix), a non-hormonal oral medication for treating moderate to severe endometriosis-related pain by inhibiting estrogen production.
AstraZeneca
Founded in 1999 and headquartered in Cambridge, UK, AstraZeneca is a major pharmaceutical player. The company developed Zoladex (goserelin), a GnRH agonist used to manage symptoms of endometriosis by suppressing estrogen levels and reducing inflammation and pain.
Other companies include ObsEva, Teva Pharmaceuticals, Astellas Pharma Inc., and Eli Lilly and Company.
Key Questions Answered in the Endometriosis Market
Endometriosis Market Overview
Endometriosis is a persistent condition, characterized by the growth of tissue like the uterine lining outside the uterus, leading to pain and potential infertility, The market for endometriosis treatment is expanding due to the increasing incidence of the condition, which affects approximately 10% of the women worldwide. Key trends contributing to this growth include heightened investment in clinical trials and the development of non-hormonal treatment options. This awareness of the condition and ongoing innovation in therapeutic solutions will significantly drive the market in the forecast period.
Endometriosis Market Growth Drivers
Rising Prevalence of Endometriosis Drives Market Growth
The rising prevalence of endometriosis has significantly contributed to the growth of the market. As reported by the World Health Organization (WHO), approximately 10% (190 million) of reproductive-age women and girls are affected by this condition globally. This alarming statistic highlights the urgent need for innovative therapies and comprehensive treatment options, thereby driving market expansion and investment opportunities in the healthcare sector.
Endometriosis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Increased Funding Initiatives to Drive Market Growth
The market is witnessing transformative trends driven by increased funding initiatives from various government and non-government organizations to support endometriosis research. For instance, in March 2023, the Wellbeing of Women and the Scottish Government allocated EUR 250,000 to fund a clinical trial for a new endometriosis treatment in over 40 years. This grant facilitated the EPIC2 trial, led by researchers at the Universities of Edinburgh, Aberdeen, and Birmingham, and involving 100 women across Edinburgh and London. The trial focused on evaluating dichloroacetate as a non-hormonal, non-invasive pain management alternative, underscoring the market's shift towards innovative therapies that meet patient needs.
Increased R&D Initiatives Poised to Elevate Endometriosis Market Value
Increased research and development initiatives are expected to elevate the market value in the coming years. For instance, in September 2023, researchers at the Comprehensive Center for Pain and Addiction examined the role of the hormone prolactin in endometriosis-related pain. Their systematic review of 18 studies revealed elevated prolactin levels in affected women, pointing to its implications for pain sensitivity. Such investigations may enhance treatment approaches, addressing both endometriosis and associated pain disorders effectively.
Clinical Trial Applications to Fuel Endometriosis Market Demand
The market continues to evolve, driven by innovative clinical trial applications that aim to enhance treatment options. For instance, in May 2023, Abbott applied for the launch of modified-release dydrogesterone tablets to the Drugs Controller General of India. It is specifically designed to manage pelvic pain associated with endometriosis. This application included requests for permission to conduct a bioequivalence study and Phase-III clinical trials, which focused on comparing the efficacy of modified-release and immediate-release formulations. The trials aimed to assess quality of life improvements and reductions in endometriosis size among participants, thereby addressing critical unmet needs in the market and potentially expanding therapeutic options for patients.
Increased Focus on Inflammation Management to Drive Endometriosis Market Growth
The increasing awareness around the role of inflammation in endometriosis has significantly influenced market dynamics, driving research and development in this area. For instance, in February 2023, Chugai Pharmaceutical Co. Ltd, in collaboration with Tsukuba Primate Research Center, NIBIOHN, and Jichi Medical University Saitama Medical Center, announced research on AMY109, a promising investigational therapy aimed at managing inflammation linked to endometriosis. This focus on inflammation management highlights a growing trend, positioning the endometriosis market for expansion.
Endometriosis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Deeply Infiltrating Endometriosis
- Superficial Peritoneal Endometriosis
- Endometriomas
- Others
- NSAIDs
- Oral Contraceptive
- Gonadotropin Releasing Hormone
- Others
- Oral
- Injectable
- Others
- Pain Medication
- Hormone Therapy
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Market Share by Route of Administration Set to Witness Significant Growth
Based on the route of administration the market is divided into oral, injectables, and others. Among these, the oral route is expected to dominate the market. Innovative oral medicines, such as Elagolix, Danazol, etc, with their potential for convenience, patient compliance, and cost-effectiveness, account for a significant share of the overall pharmaceutical landscape. This segment is poised for significant expansion during the forecast period, largely due to increasing awareness and demand for patient-friendly treatment options.
Endometriosis Market Analysis by Region
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to dominate the market due to advanced technology, strong consumer demand, and substantial investments in innovation. This region is poised for future growth with increasing adoption of digital solutions, and rising health consciousness among consumers. Additionally, the government initiatives in healthcare infrastructure enhance competitiveness, making this region a key driver of market expansion in the forecast period.
Leading Players in the Endometriosis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a global life sciences company. For endometriosis, Bayer has developed Visanne (dienogest), a progestin-only oral treatment approved for managing endometriosis symptoms by reducing pelvic pain and lesions.
Pfizer Inc.
Established in 1849, Pfizer is based in New York City, USA. The company has developed Depo-Provera (medroxyprogesterone acetate), primarily a contraceptive, but also used for treating endometriosis-related symptoms such as pelvic pain.
AbbVie Inc.
AbbVie, founded in 2013 and headquartered in North Chicago, Illinois, USA, is renowned for its biopharmaceuticals. The company developed Orilissa (elagolix), a non-hormonal oral medication for treating moderate to severe endometriosis-related pain by inhibiting estrogen production.
AstraZeneca
Founded in 1999 and headquartered in Cambridge, UK, AstraZeneca is a major pharmaceutical player. The company developed Zoladex (goserelin), a GnRH agonist used to manage symptoms of endometriosis by suppressing estrogen levels and reducing inflammation and pain.
Other companies include ObsEva, Teva Pharmaceuticals, Astellas Pharma Inc., and Eli Lilly and Company.
Key Questions Answered in the Endometriosis Market
- What was the endometriosis market value in 2024?
- What is the endometriosis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market breakup by type?
- What is the market segmentation based on the drug class?
- What is the market breakup based on the route of administration?
- What is the market segmentation based on the treatment type?
- What is the market breakup based on the distribution channel?
- What are the major factors aiding the endometriosis market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major endometriosis market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the endometriosis market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Endometriosis Market Overview – 8 Major Markets
- 3.1 Endometriosis Market Historical Value (2018-2024)
- 3.2 Endometriosis Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Endometriosis Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Endometriosis Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 Japan
- 7.2.8 India
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 Italy
- 7.3.6 Spain
- 7.3.7 Japan
- 7.3.8 India
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 Italy
- 7.4.6 Spain
- 7.4.7 Japan
- 7.4.8 India
- 8 Endometriosis Market Landscape – 8 Major Markets
- 8.1 Endometriosis Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Endometriosis Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Route of Administration
- 8.2.4 Analysis by Treatment Type
- 9 Endometriosis Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Endometriosis Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Endometriosis Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Endometriosis Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Deeply Infiltrating Endometriosis
- 12.1.3 Superficial Peritoneal Endometriosis
- 12.1.4 Endometriomas
- 12.1.5 Others
- 12.2 Endometriosis Market (2018-2034) by Drug Class
- 12.2.1 Market Overview
- 12.2.2 NSAIDs
- 12.2.3 Oral Contraceptive
- 12.2.4 Gonadotropin Releasing Hormone
- 12.2.5 Others
- 12.3 Endometriosis Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Injectable
- 12.3.4 Others
- 12.4 Endometriosis Market (2018-2034) by Treatment Type
- 12.4.1 Market Overview
- 12.4.2 Pain Medication
- 12.4.3 Hormone Therapy
- 12.5 Endometriosis Market (2018-2034) by Distribution Channel
- 12.5.1 Market Overview
- 12.5.2 Hospital Pharmacies
- 12.5.3 Retail Pharmacies
- 12.5.4 Online Pharmacies
- 12.5.5 Others
- 12.6 Endometriosis Market (2018-2034) by End User
- 12.6.1 Market Overview
- 12.6.2 Hospitals
- 12.6.3 Specialty Clinics
- 12.6.4 Others
- 12.7 Endometriosis Market (2018-2034) by Region
- 12.7.1 Market Overview
- 12.7.2 United States
- 12.7.3 United Kingdom
- 12.7.4 Germany
- 12.7.5 France
- 12.7.6 Italy
- 12.7.7 Spain
- 12.7.8 Japan
- 12.7.9 India
- 13 United States Endometriosis Market (218-2034)
- 13.1 United States Endometriosis Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Deeply Infiltrating Endometriosis
- 13.1.3 Superficial Peritoneal Endometriosis
- 13.1.4 Endometriomas
- 13.1.5 Others
- 13.2 United States Endometriosis Market (2018-2034) by Drug Class
- 13.2.1 Market Overview
- 13.2.2 NSAIDs
- 13.2.3 Oral Contraceptive
- 13.2.4 Gonadotropin Releasing Hormone
- 13.2.5 Others
- 13.3 United States Endometriosis Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Injectable
- 13.3.4 Others
- 13.4 United States Endometriosis Market (2018-2034) by Treatment Type
- 13.4.1 Market Overview
- 13.4.2 Pain Medication
- 13.4.3 Hormone Therapy
- 13.5 United States Endometriosis Market (2018-2034) by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacies
- 13.5.3 Retail Pharmacies
- 13.5.4 Online Pharmacies
- 13.5.5 Others
- 13.6 United States Endometriosis Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals
- 13.6.3 Specialty Clinics
- 13.6.4 Others
- 14 United Kingdom Endometriosis Market (218-2034)
- 14.1 United Kingdom Endometriosis Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 Deeply Infiltrating Endometriosis
- 14.1.3 Superficial Peritoneal Endometriosis
- 14.1.4 Endometriomas
- 14.1.5 Others
- 14.2 United Kingdom Endometriosis Market (2018-2034) by Drug Class
- 14.2.1 Market Overview
- 14.2.2 NSAIDs
- 14.2.3 Oral Contraceptive
- 14.2.4 Gonadotropin Releasing Hormone
- 14.2.5 Others
- 14.3 United Kingdom Endometriosis Market (2018-2034) by Route of Administration
- 14.3.1 Market Overview
- 14.3.2 Oral
- 14.3.3 Injectable
- 14.3.4 Others
- 14.4 United Kingdom Endometriosis Market (2018-2034) by Treatment Type
- 14.4.1 Market Overview
- 14.4.2 Pain Medication
- 14.4.3 Hormone Therapy
- 14.5 United Kingdom Endometriosis Market (2018-2034) by Distribution Channel
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacies
- 14.5.3 Retail Pharmacies
- 14.5.4 Online Pharmacies
- 14.5.5 Others
- 14.6 United Kingdom Endometriosis Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals
- 14.6.3 Specialty Clinics
- 14.6.4 Others
- 15 Germany Endometriosis Market (218-2034)
- 15.1 Germany Endometriosis Market (2018-2034) by Type
- 15.1.1 Market Overview
- 15.1.2 Deeply Infiltrating Endometriosis
- 15.1.3 Superficial Peritoneal Endometriosis
- 15.1.4 Endometriomas
- 15.1.5 Others
- 15.2 Germany United Kingdom Endometriosis Market (2018-2034) by Drug Class
- 15.2.1 Market Overview
- 15.2.2 NSAIDs
- 15.2.3 Oral Contraceptive
- 15.2.4 Gonadotropin Releasing Hormone
- 15.2.5 Others
- 15.3 Germany Endometriosis Market (2018-2034) by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.3 Injectable
- 15.3.4 Others
- 15.4 Germany Endometriosis Market (2018-2034) by Treatment Type
- 15.4.1 Market Overview
- 15.4.2 Pain Medication
- 15.4.3 Hormone Therapy
- 15.5 Germany Endometriosis Market (2018-2034) by Distribution Channel
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacies
- 15.5.3 Retail Pharmacies
- 15.5.4 Online Pharmacies
- 15.5.5 Others
- 15.6 Germany Endometriosis Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals
- 15.6.3 Specialty Clinics
- 15.6.4 Others
- 16 France Endometriosis Market (218-2034)
- 16.1 France Endometriosis Market (2018-2034) by Type
- 16.1.1 Market Overview
- 16.1.2 Deeply Infiltrating Endometriosis
- 16.1.3 Superficial Peritoneal Endometriosis
- 16.1.4 Endometriomas
- 16.1.5 Others
- 16.2 France Endometriosis Market (2018-2034) by Drug Class
- 16.2.1 Market Overview
- 16.2.2 NSAIDs
- 16.2.3 Oral Contraceptive
- 16.2.4 Gonadotropin Releasing Hormone
- 16.2.5 Others
- 16.3 France Endometriosis Market (2018-2034) by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.3 Injectable
- 16.3.4 Others
- 16.4 France Endometriosis Market (2018-2034) by Treatment Type
- 16.4.1 Market Overview
- 16.4.2 Pain Medication
- 16.4.3 Hormone Therapy
- 16.5 France Endometriosis Market (2018-2034) by Distribution Channel
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacies
- 16.5.3 Retail Pharmacies
- 16.5.4 Online Pharmacies
- 16.5.5 Others
- 16.6 France Endometriosis Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals
- 16.6.3 Specialty Clinics
- 16.6.4 Others
- 17 Italy Endometriosis Market (218-2034)
- 17.1 Italy Endometriosis Market (2018-2034) by Type
- 17.1.1 Market Overview
- 17.1.2 Deeply Infiltrating Endometriosis
- 17.1.3 Superficial Peritoneal Endometriosis
- 17.1.4 Endometriomas
- 17.1.5 Others
- 17.2 Italy Endometriosis Market (2018-2034) by Drug Class
- 17.2.1 Market Overview
- 17.2.2 NSAIDs
- 17.2.3 Oral Contraceptive
- 17.2.4 Gonadotropin Releasing Hormone
- 17.2.5 Others
- 17.3 Italy Endometriosis Market (2018-2034) by Route of Administration
- 17.3.1 Market Overview
- 17.3.2 Oral
- 17.3.3 Injectable
- 17.3.4 Others
- 17.4 Italy Endometriosis Market (2018-2034) by Treatment Type
- 17.4.1 Market Overview
- 17.4.2 Pain Medication
- 17.4.3 Hormone Therapy
- 17.5 Italy Endometriosis Market (2018-2034) by Distribution Channel
- 17.5.1 Market Overview
- 17.5.2 Hospital Pharmacies
- 17.5.3 Retail Pharmacies
- 17.5.4 Online Pharmacies
- 17.5.5 Others
- 17.6 Italy Endometriosis Market (2018-2034) by End User
- 17.6.1 Market Overview
- 17.6.2 Hospitals
- 17.6.3 Specialty Clinics
- 17.6.4 Others
- 18 Spain Endometriosis Market (218-2034)
- 18.1 Spain Endometriosis Market (2018-2034) by Type
- 18.1.1 Market Overview
- 18.1.2 Deeply Infiltrating Endometriosis
- 18.1.3 Superficial Peritoneal Endometriosis
- 18.1.4 Endometriomas
- 18.1.5 Others
- 18.2 Spain Treatment Market (2018-2034) by Drug Class
- 18.2.1 Market Overview
- 18.2.2 NSAIDs
- 18.2.3 Oral Contraceptive
- 18.2.4 Gonadotropin Releasing Hormone
- 18.2.5 Others
- 18.3 Spain Endometriosis Market (2018-2034) by Route of Administration
- 18.3.1 Market Overview
- 18.3.2 Oral
- 18.3.3 Injectable
- 18.3.4 Others
- 18.4 Spain Endometriosis Market (2018-2034) by Treatment Type
- 18.4.1 Market Overview
- 18.4.2 Pain Medication
- 18.4.3 Hormone Therapy
- 18.5 Spain Endometriosis Market (2018-2034) by Distribution Channel
- 18.5.1 Market Overview
- 18.5.2 Hospital Pharmacies
- 18.5.3 Retail Pharmacies
- 18.5.4 Online Pharmacies
- 18.5.5 Others
- 18.6 Spain Endometriosis Market (2018-2034) by End User
- 18.6.1 Market Overview
- 18.6.2 Hospitals
- 18.6.3 Specialty Clinics
- 18.6.4 Others
- 19 Japan Endometriosis Market (218-2034)
- 19.1 Japan Endometriosis Market (2018-2034) by Type
- 19.1.1 Market Overview
- 19.1.2 Deeply Infiltrating Endometriosis
- 19.1.3 Superficial Peritoneal Endometriosis
- 19.1.4 Endometriomas
- 19.1.5 Others
- 19.2 Japan Endometriosis Market (2018-2034) by Drug Class
- 19.2.1 Market Overview
- 19.2.2 NSAIDs
- 19.2.3 Oral Contraceptive
- 19.2.4 Gonadotropin Releasing Hormone
- 19.2.5 Others
- 19.3 Japan Endometriosis Market (2018-2034) by Route of Administration
- 19.3.1 Market Overview
- 19.3.2 Oral
- 19.3.3 Injectable
- 19.3.4 Others
- 19.4 Japan Endometriosis Market (2018-2034) by Treatment Type
- 19.4.1 Market Overview
- 19.4.2 Pain Medication
- 19.4.3 Hormone Therapy
- 19.5 Japan Endometriosis Market (2018-2034) by Distribution Channel
- 19.5.1 Market Overview
- 19.5.2 Hospital Pharmacies
- 19.5.3 Retail Pharmacies
- 19.5.4 Online Pharmacies
- 19.5.5 Others
- 19.6 Japan Endometriosis Market (2018-2034) by End User
- 19.6.1 Market Overview
- 19.6.2 Hospitals
- 19.6.3 Specialty Clinics
- 19.6.4 Others
- 20 India Endometriosis Market (218-2034)
- 20.1 India Endometriosis Market (2018-2034) by Type
- 20.1.1 Market Overview
- 20.1.2 Deeply Infiltrating Endometriosis
- 20.1.3 Superficial Peritoneal Endometriosis
- 20.1.4 Endometriomas
- 20.1.5 Others
- 20.2 India Endometriosis Market (2018-2034) by Drug Class
- 20.2.1 Market Overview
- 20.2.2 NSAIDs
- 20.2.3 Oral Contraceptive
- 20.2.4 Gonadotropin Releasing Hormone
- 20.2.5 Others
- 20.3 India Endometriosis Market (2018-2034) by Route of Administration
- 20.3.1 Market Overview
- 20.3.2 Oral
- 20.3.3 Injectable
- 20.3.4 Others
- 20.4 India Endometriosis Market (2018-2034) by Treatment Type
- 20.4.1 Market Overview
- 20.4.2 Pain Medication
- 20.4.3 Hormone Therapy
- 20.5 India Endometriosis Market (2018-2034) by Distribution Channel
- 20.5.1 Market Overview
- 20.5.2 Hospital Pharmacies
- 20.5.3 Retail Pharmacies
- 20.5.4 Online Pharmacies
- 20.5.5 Others
- 20.6 India Endometriosis Market (2018-2034) by End User
- 20.6.1 Market Overview
- 20.6.2 Hospitals
- 20.6.3 Specialty Clinics
- 20.6.4 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Drug Class of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 23 Clinical Trials Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Drug Class of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Drug Class of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 Bayer AG
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Developments
- 27.2.5 Certifications
- 27.3 Pfizer Inc.
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Developments
- 27.3.5 Certifications
- 27.4 Abbvie Inc.
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Developments
- 27.4.5 Certifications
- 27.5 Astrazeneca
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Developments
- 27.5.5 Certifications
- 27.6 ObsEva
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Developments
- 27.6.5 Certifications
- 27.7 Teva Pharmaceuticals
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Developments
- 27.7.5 Certifications
- 27.8 Eli Lilly and Company
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Developments
- 27.8.5 Certifications
- 27.9 Astellas Pharma Inc.
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Developments
- 27.9.5 Certifications
- 28 Endometriosis Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
